New hope for patients with aggressive blood cancer that has stopped responding to treatment
NCT ID NCT07096778
Summary
This study is testing whether adding a new drug called inobrodib to two standard medications can help control multiple myeloma that has come back and no longer responds to available therapies. It will involve about 100 adults whose cancer has progressed despite trying several other treatments. The main goal is to see if this three-drug combination can shrink the cancer and for how long, while also carefully tracking side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITINGLondon, W12 0HS, United Kingdom
-
Royal Marsden NHS Foundation Trust
RECRUITINGSutton, London, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.